PDF Print E-mail

Recent Data Highlight Bavituximab's Immuno-Oncology Potential

Bavituximab and other PS-targeting antibodies have shown consistently encouraging signs of anti-tumor activity in multiple preclinical studies including models of lung, pancreatic, breast, prostate and brain cancer. Recent studies have also identified multiple immuno-stimulatory mechanisms induced by bavituximab and other PS-targeting antibodies that likely contribute to their observed anti-tumor effects.

2014 AACR Annual Meeting


  • Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer. View poster
  • Phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model. View poster
  • Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances Activity of Immune Checkpoint Inhibitors in Tumors. View poster


2014 Keystone Symposium: Immune Evolution in Cancer

  • Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor- Specific Immunity. View poster,  View presentation slides
  • Phosphatidylserine Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors. View poster

2014 Keystone Symposium: HIV Pathogenesis - Virus vs. Host

  • Phosphotidylserine-targeting antibody Triggers β-Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a potent inhibitor of HIV-1 in vitro. View poster

2014 ITOC-1 Immunotherapy of Cancer Conference

2013 Society for Immunotherapy of Cancer Annual Meeting

  • Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses. View poster
  • Phosphatidylserine-Targeting  Antibody  Induces  M1  Macrophage  Polarization,  Promotes  Myeloid  Derived   Suppressor  Cell  Differentiation,  Boosts  Tumor-­Specific  Immunity. View poster

2013 Cambridge Healthtech Immunotherapy Congress

  • Engagement of Phosphatidylserine (PS) by PS-Targeting Antibodies Blocks an Upstream Immunosuppressive Checkpoint in the Tumor Microenvironment Inducing Multiple Downstream Anti-Tumor Response Mechanisms View presentation slides

2013 AACR Annual Meeting

  • Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice. View poster
  • Predicting Anti-tumor Responses to Phosphatidylserine Targeting Antibodies Using Tumor Imaging. View poster
  • Phosphatidylserine-Targeting ‘Betabodies’ for the Treatment of Cancer. View poster

New York Academy of Sciences Symposium: May 1, 2012

Phosphatidylserine Asymmetry and Cell Survival: Therapeutic Applications in Cancer and Infectious Disease

On May 1, 2012, the New York Academy of Sciences (NYAS) hosted a symposium covering the topics of the role that phosphatidylserine (PS) plays in suppressing immune response and therapeutic applications of targeting PS. Philip Thorpe, PhD, inventor or Peregrine's PS-targeting antibody technology and scientific advisor to the company, gave the final presentation, titled, Targeting Tumor Vasculature and Reactivating Tumor Immunity with Bavituximab. The entire symposium including audio replay and presentation slides are available o n the NYAS website as an e-briefing.

2012 Society for Immunotherapy of Cancer Annual Meeting

  • Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses. View poster

2012 AACR Annual Meeting Clinical Poster Presentations

  • A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naïve stage IV non-squamous non-small cell lung cancer. View poster
  • A Phase I Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. View poster
  • Microparticle Generation and Activation after Treatment with Paclitaxel and Bavituximab Combination Therapy in Metastatic Breast Cancer. View poster

2012 AACR Annual Meeting Preclinical Poster Presentations

  • Tumor Detection and Measurement of Responses to Chemotherapy Using Human Phosphatidylserine Targeting Antibody Fragments. View poster
  • Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody. View poster
  • Increased Fc-FcR Interaction of Human Phosphatidylserine Targeting Antibody Enhances Pro-Inflammatory and ADCC Mechanisms. View poster
  • In Vivo Binding of chTNT-1/B Antibodies (Cotara) to DNA/Histone Complexes in Tumors Using Near-Infrared Optical Imaging. View poster

2012 AACR Pancreatic Cancer Conference: Progress and Challenges

  • A randomized, open-label phase 2 trial of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer. View poster

2011 World Molecular Imaging Congress Poster Presentations

  • Imaging of Human Tumor Xenografts in Mice Using Near-Infrared Fluorescent-Labeled Phosphatidylserine Targeting Antibodies View poster...
  • Multimodal Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model View poster...

2011 AACR Annual Meeting Poster Presentations:

  • Prostate Cancer: Targeting Phosphatidylserine to Improve Hormone Therapy of Prostate Cancer. View poster...
  • Advanced Liver Cancer: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity Against Human Hepatocellular Carcinomas in Mice. View poster...
  • Mechanism of Action: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages. View poster...
  • Prostate Cancer: PS-Targeting Antibody Enhances Survival Benefit of Androgen Deprivation Therapy of Mice Bearing Syngeneic Prostate Cancer. View poster...

2010 AACR Annual Meeting Poster Presentations:

  • Mechanism of Action: Phosphatidylserine on Dying Tumor Cells Suppresses Dendritic Cell Activation and Inhibits Tumor Immunity: Reversal with PS-Targeting Antibody. View poster...
  • Imaging: Phosphatidylethanolamine is a marker of tumor vasculature and can be used as a target for optical imaging. View poster...
  • Imaging: Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine-Targeting Antibodies. View poster...

Bavituximab in Action

Experiments in animals have shown that bavituximab recruits immune cells into the tumor environment.

Before Therapy

After Therapy
Blue: tumor cell nuclei
Red: blood vessels
Green: immune cells (macrophages)

Read about the growing body of published research validating bavituximab’s broad-spectrum potential...